Agilent Technologies Inc (A)
$173.96 $1.12 (0.65%) 4:20 PM 11/13/2026
NYSE | $USD | Diagnostics & ResearchStock Data
-
Market Cap
$49.28B -
Day's Range
$170.71 - $174.62 -
Volume
1,999,547 -
52 Week Low / High
$108.35 - $182.99 -
PE Ratio
34.47x -
PEG Ratio
- -
Dividend Frequency
quarterly
Analyst ratings: Buy 15, Hold 7, Sell 0.
Company News
-
Agilent Technologies (A) Launches New Cancer Panel As Valuation Stays In Focus — Nov 12, 2026
Agilent Technologies (A) has broadened its cancer research toolkit with the SureSelect Cancer Research Pan Heme panel, a next generation sequencing solution tailored to genomic profiling of blood related tumors. Recent product launches in genomic profiling and mass spectrometry are landing...
-
Agilent to Participate in 9th Annual Evercore Healthcare Conference — Nov 12, 2026
SANTA CLARA, Calif., November 12, 2026--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in the upcoming 9th Annual Evercore Healthcare Conference. Agilent management is scheduled to participate in a fireside chat from 10 a.m. to 10:50 ...
-
Learn Why The Bull Case For Agilent Stock Could Change Following Pan Heme Launch — Nov 12, 2026
Agilent Technologies recently introduced the SureSelect Cancer Research Pan Heme, a hybrid capture NGS panel that integrates DNA and RNA profiling, automation and bioinformatics to study 359 DNA genes and 124 RNA genes in hematologic malignancy research. The new panel, codeveloped with Ros...
-
Agilent Technologies (A) Expands Tumor Profiling With New Pan Heme Research Panel — Nov 12, 2026
Agilent Technologies (NYSE:A) introduced the SureSelect Cancer Research Pan Heme panel for tumor profiling in hematologic malignancies. The new assay is co-developed with hematology experts to support comprehensive genomic profiling in blood cancer research workflows. SureSelect Cancer Res...
-
Mass Spectrometry - Global Strategic Business Report 2026-2032 Featuring Thermo Fisher, Agilent, Bruker, Shimadzu, Waters and More — Nov 11, 2026
Company Logo Capitalize on demand for high-sensitivity MS, hybrid LC-MS/GC-MS platforms, and software-led services across biopharma, diagnostics, food safety and environmental testing Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Mass Spectrometry - Global Strategic Business Report" has been ...
-
Company Logo Target reagents, personalized medicine, single-cell sequencing and diagnostics; leverage tariff and regional insights to optimize sourcing, investment and revenue opportunities. Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "RNA Analysis / Transcriptomics - Global Strategic Busine...
-
Company Logo Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Single-Cell Analysis - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global single-cell analysis market was valued at US$7.1 billion in 2025 and is projected to reach US$26.1 billion b...
-
Company Logo Capitalize on personalized medicine, advanced genetic testing and cancer diagnostics with tariff-aware sourcing, regional analysis and competitive insights. Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Molecular Cytogenetics - Global Strategic Business Report" has been added to ...
-
Company Logo Capitalize on NGS, AI-enabled bioinformatics, direct-to-consumer testing and personalized medicine, guided by tariff, regional and competitive insights. Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Genetic Testing - Global Strategic Business Report" has been added to ResearchAnd...
-
Company Logo Capitalize on CE-MS, automation and microchip CE to boost throughput, cut reagent use, and target pharma, biotech, diagnostics and high-growth Asian markets. Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Capillary Electrophoresis - Global Strategic Business Report" has been added...
Portfolio
Comprised of 1 portfolios



